SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
_____________________

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 1)1

Milestone Pharmaceuticals Inc.
(Name of Issuer)
 
Common Stock, no par value
(Title of Class of Securities)
 
59935V107
(CUSIP Number)
 
December 31, 2020
Date of Event Which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:

[   ] Rule 13d-1(b)
[   ] Rule 13d-1(c)
[X] Rule 13d-1(d)




_______________________

1The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.







CUSIP Number:  59935V107


1)
Name of Reporting Person
I.R.S. Identification
No. of Above Person
(Entities Only)
(Voluntary)
Domain Partners VIII, L.P.
2)
Check the Appropriate Box
if a Member of a Group
(a) [X]
(b) [ ]
3)
SEC Use Only
 
4)
Citizenship or Place
of Organization
Delaware
Number of
Shares Beneficially
Owned by Each
Reporting Person
With
5)
Sole Voting
Power
860,724 shares of Common Stock *
6)
Shared Voting
Power
 
-0-
7)
Sole Dispositive
Power
860,724 shares of Common Stock *
8)
Shared Dispositive Power
 
-0-
9)
Aggregate Amount Beneficially Owned by Each Reporting Person
860,724 shares of Common Stock *
10)
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
 
11)
Percent of Class Represented by Amount in Row (9)
2.9% **
12)
Type of Reporting Person
PN
 
* As of December 31, 2020
** Based on 29,822,897 shares of Common Stock outstanding as of November 6, 2020, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2020 filed with the Securities and Exchange Commission on November 13, 2020







2
CUSIP Number:  59935V107


Amendment No. 1 to Schedule 13G (FINAL AMENDMENT)

Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Person with respect to the Common Stock of the Issuer on January 9, 2020 (the “Schedule 13G”).  Terms defined in the Schedule 13G are used herein as so defined.

The following items of the Schedule 13G are hereby amended and restated as follows:

Item 4 –  Ownership.

(a) through (c):

The information requested in these paragraphs is incorporated herein by reference to the cover page to this Amendment No. 1 to Schedule 13G.

Item 5 –  Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that the Reporting Person has ceased to be the beneficial owner of more than five percent of the Common Stock, check the following:  [X]








3
CUSIP Number:  59935V107


Signature

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Dated:  January 20, 2021

 
DOMAIN PARTNERS VIII, L.P.
 
By:
One Palmer Square Associates VIII, L.L.C., General Partner
 
 
By:
/s/ Lisa A. Kraeutler
   
Attorney-in-Fact








4
Milestone Pharmaceuticals (NASDAQ:MIST)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Milestone Pharmaceuticals Charts.
Milestone Pharmaceuticals (NASDAQ:MIST)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Milestone Pharmaceuticals Charts.